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Abstract
Aims—Exposure to human adenovirus Ad36 is causatively and correlatively linked with better 
glycemic control in animals and humans, respectively. Although the anti-hyperglycemic property 
of Ad36 may offer some therapeutic potential, it is impractical to use an infectious agent for 
therapeutic benefit. Cell- based studies identified that Ad36 enhances cellular glucose disposal via 
its E4orf1 protein. Ability to improve glycemic control in vivo is a critical prerequisite for further 
investigating the therapeutic potential of E4orf1. Therefore, the aim of this study was to determine 
the ability of E4orf1 to improve glycemic control independent of insulin despite high fat diet.
Materials & Methods—8–9wk old male C57BL/6J mice fed a high-fat diet (60% kcal) were 
injected with a retrovirus plasmid expressing E4orf1, or a null vector (Control). Glycemic control 
was determined by glucose and insulin tolerance test. Islet cell size, amount of insulin and 
glucagon were determined in formalin-fixed pancreas. Rat insulinoma cell line (832/13) was 
infected with E4orf1 or control to determine changes in glucose stimulated insulin secretion. 
Protein from flash frozen adipose tissue depots, liver and muscle was used to determine molecular 
signaling by western blotting.
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Results—In multiple experiments, retrovirus-mediated E4orf1 expression in C57BL/6J mice 
significantly and reproducibly improved glucose excursion following a glucose load despite a high 
fat diet (60% energy). Importantly, E4orf1 improved glucose clearance without increasing insulin 
sensitivity, production or secretion, underscoring its insulin-independent effect. E4orf1 modulated 
molecular signaling in mice tissue, which included greater protein abundance of adiponectin, p-
AKT and Glucose transporter Glu4.
Conclusions—This study provides the proof of concept for translational development of E4orf1 
as a potential anti-diabetic agent. High fat intake and impaired insulin signaling are often 
associated with obesity, diabetes and insulin resistance. Hence, the ability of E4orf1 to improve 
glycemic control despite high fat diet and independent of insulin, is particularly attractive.
Keywords
Adenoviral protein; Glycemic control; Diabetes; Anti-diabetic drug; Glucose disposal; Insulin-
independent effect
1. Introduction
Although about a dozen classes of anti-diabetes drugs are available, considerable need for 
better anti-diabetes drugs persists [1]. For example, high fat intake or impaired insulin 
signaling are often associated with diabetes. Yet, the current anti-diabetes drugs are insulin 
sensitizers, insulin mimetic or secretagogues, requiring insulin signaling for optimal 
benefits. Therefore, drugs that improve diabetes independent of dietary fat intake and insulin 
action may offer a significant advantage [2]. Here we describe such potential of the E4orf1 
protein of human adenovirus Ad36, which may be translated to develop new anti-diabetic 
agents.
Microbes are a somewhat unconventional yet important source to develop therapeutic agents 
and strategies [3]. In animal models, Ad36 increases adiposity, but enhances glycemic 
control and reduces hepatic lipid accumulation, despite high fat diet and without recruiting 
the proximal insulin signaling [4–7]. Ad36 appears to enhance systemic glycemic control by 
promoting glucose uptake by adipose tissue and skeletal muscle, and by reducing hepatic 
glucose output and hepatic steatosis [8,9]. In rhesus monkeys, natural exposure to Ad36 is 
linked with a reduction in fasting glucose levels [10]. Interestingly, as cross-sectional and 
prospective associations, the key findings from Ad36-infected animals are mirrored in 
humans who are naturally exposed to Ad36 infection [4,11–22]. In humans, natural exposure 
to Ad36 is associated with obesity and fat gain, yet lower liver lipids and better glycemic 
control [4,11–22]. Natural Ad36 infection has also been shown to be associated with lower 
occurrence of type 2 diabetes with increased insulin sensitivity [23].
The potential of Ad36 to improve glycemic control is highly attractive for developing an 
effective anti-diabetic agent. Nonetheless, it is impractical to use a viral infection to improve 
diabetes. Instead, in vitro experiments identified that the E4orf1 protein, a 125 amino acid 
peptide [24], increases cellular glucose uptake in preadipocytes, adipocytes, and myoblasts, 
and reduces glucose output from hepatocytes [25,26]. These studies showed that E4orf1 
bypassed the IRS mediated proximal insulin signaling and improved cellular glucose by up-
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regulating the distal insulin signaling involving phosphatidyl insositol 3-kinase (PI3K), Akt 
and glucose transporter 4 (Glut4), via Ras activation [27]. These observations collectively 
showed that unlike the current anti-diabetic drugs, E4orf1 did not function as an insulin 
sensitizer, mimetic or secretagogue, but exhibited an insulin sparing effect [27]. This finding 
provided a single protein instead of an infectious agent, as a candidate to further investigate 
the anti-diabetic potential of Ad36 in vivo. Either the E4orf1 protein itself, or its analogs 
may be useful for developing therapeutic agent(s), provided, the protein improves glycemic 
control in vivo.
A proof of concept that E4orf1 protein enhances glycemic control in vivo is essential for 
further translating therapeutic properties of E4orf1. Hence, in multiple experiments, with the 
help of a retrovirus vector (pBabe), we expressed Ad36 E4orf1 gene in high fat fed male 
C57BL/6J mice to determine the effect on glucose and insulin response and related cell 
signaling, and to assess the duration and reproducibility of the effect. As described below, 
the results demonstrated that E4orf1 is capable of improving glycemic control in vivo. This 
in vivo validation should stimulate further research towards developing E4orf1-based 
therapeutic agents.
2. Materials & Methods
2.1 Animal experiments
Institutional Animal Care and Use Committee (IACUC) of the Pennington Biomedical 
Research Center approved the protocols for animal studies. Mice were purchased from The 
Jackson Laboratories (Bar Harbour, Maine, USA) and placed on a 12 h light-dark cycle at 
25 °C and housed in micro-isolator cages under Biosafety level-2 containment, with ad 
libitum access to food and water. End of study sacrifice was conducted by CO2 asphyxiation 
followed by cervical dislocation. Based on a previous study [4] power analysis showed that a 
total of 6–9 mice were required in this parallel design study, at 90% probability to detect a 
treatment difference at a two-sided significance at 0.05.
Experiment 1: Does E4orf1 enhance blood glucose excursion in high fat fed 
mice?—Six-week old C57Bl/6J male mice on rodent chow (Purina Lab Diet 5001) were 
allowed 1-week of acclimatization following which total body fat was determined by Bruker 
Minispec mq10-NMR (Nuclear Magnetic Resonance) analyzer. Baseline GTT was 
performed as described under methods, to determine blood glucose clearance. The animals 
were then placed on a high fat (HF, 60% kcal) diet (Research Diets Inc. D12492i) for 2 
weeks and GTT performed to determine HF diet induced hyperglycemia. Mice were divided 
into two groups (n = 9 each; Control or E4orf1) matched for body weight and inoculated 
with 300 μL pBabe-puro (Control) or pBabe-E4orf1 (108 copies of E4orf1) retrovirus as a 
combination of intra-peritoneal (i.p.), intra muscular (I.M.) and subcutaneous injections. 
GTT was performed 1 week post-infection (p.i.).
Experiment 2: Does E4orf1 transiently but reproducibly enhance glucose 
excursion?—Nine week old C57Bl/6J male mice on HF diet since 6 week of age were 
weight matched, divided into two groups and inoculated with pBabe-puro (Control; n = 6) or 
pBabe-E4orf1 (E4orf1; n = 6) retrovirus as described in Experiment 1. GTT was performed 
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1, 2, 3 and 4 week p.i. Mice were re-inoculated on week 7 p.i. and GTT performed 4 and 7 
days post re-inoculation.
Experiment 3: Does a booster dose of E4orf1 extend the duration of 
enhancement in glucose clearance?—Eight week old C57Bl/6J male mice on HF diet 
since 6 wk of age, after 1 week of acclimatization and total body fat determination were 
weight matched into two groups. At 9 week of age the mice were inoculated with pBabe-
puro (Control; n = 6) or pBabe-E4orf1 (E4orf1; n = 6) retrovirus as described in Experiment 
1. GTT was performed 1 week p.i. and mice were re-inoculated at 10 week of age and GTT 
performed 1 week post re-inoculation to determine booster dose effect on blood glucose 
clearance. GTT was also performed 2 week post re-inoculation and 1 week post second 
booster inoculation.
Experiment 4: Does longer duration of high fat diet delay the improvement in 
GTT induced by E4orf1?—Eighteen C57Bl/6J male mice on HF diet since 6 week of age 
were weight matched, divided into three groups and total body fat content was determined. 
At 14 week of age the mice were inoculated with pBabe-puro (Control; n = 6) or pBabe-
E4orf1 (E4orf1 300 μL; n = 6) or pBabe-E4orf1 (E4orf1 600 μL; n = 6) retrovirus as 
described in Experiment 1. GTT was performed 1, 2 and 3 week p.i. following which the 
mice were re-inoculated with a booster dose and GTT performed 4 days post re-inoculation.
Experiment 5: Does E4orf1 improve glucose clearance without increasing 
insulin sensitivity, production or secretion?—Nine week old C57Bl/6J male mice on 
HF diet since 6 week of age were weight matched, divided into two groups and inoculated 
with pBabe-puro (Control; n = 3) or pBabe-E4orf1 (E4orf1; n = 3) retrovirus as described in 
Experiment 1. Insulin tolerance test (ITT) was performed 1 and 2 week p.i. At the time of 
sacrifice (described in Experiment 6), trunk blood was collected and serum separated from 
fasted and non-fasted control (n = 3) and E4orf1 (n = 3) mice. Serum insulin was measured 
using insulin kit (Rat/Mouse Insulin ELISA, #EZRMI-13K, Millipore). Formalin fixed 
pancreas from control (n = 3) and E4orf1 (n = 3) were sectioned and beta cell mass was 
determined by selecting insulin expressing beta cell areas. These areas were then combined 
within a slice and the total area of insulin expressing cells was divided by the total tissue 
area on the slide and multiplied by 100. This gave the percent pancreas 2D section covered 
by beta-cells. The sectioned pancreata from multiple mice were also stained for insulin and 
glucagon to measure intensity between beta and alpha cells.
Glucose stimulated insulin secretion was determined in rat insulinoma 832/13 cells. Insulin 
was measured using the High Range Rat Insulin ELISA assay kit (Mercodia) as described in 
methods.
Experiment 6: Does E4orf1 enhance cell signaling in glucose disposal 
pathway?—Fasted (4 h) Control (n = 3) and E4orf1 (n = 3) mice were sacrificed by CO2 
asphyxiation and cervical dislocation and trunk blood was collected. Liver, muscle, 
pancreas, ingunal, epididymal, and retroperitoneal fat depots were carefully separated, 
weighed, flash frozen in liquid nitrogen, and stored at −80 °C. Protein lysates from tissues 
were used for western blot analysis to determine changes in protein expression of AKT, p-
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AKT, AMPK, Glut4, adiponectin, Ras, PPARƔ, Glut2 and glucokinase in response to 
E4orf1 expression as described in methods.
2.2 Statistical analyses
Differences in glucose and insulin levels were analyzed by two-tailed student’s ‘t’ test for all 
animal experiments. Probability levels were set at p≤ 0.05. Groups for western blot analysis 
were compared using ANOVA followed by tukey’s test.
2.3 Methods
2.3.1. Retrovirus—The human Adenovirus serotype 36 (Ad36) (from ATCC) early gene 4 
open reading frame 1 (E4orf1) gene was amplified by PCR and cloned into the pBabe-puro 
retroviral vector (Cell Biolabs, Inc) at the BamHI-EcoRI site using restriction enzyme 
analysis. The constructed pBabe-E4orf1 and control pBabe-puro vectors were transformed 
into E. coli to make DNA stocks. The DNA was transfected into BOSC-23 cells (a gift from 
Dr. E. Floyd) to generate viral stocks and stored at −80 °C. BSL-2 safety measures were 
carried out during the viral stock generation and handling.
2.3.2. Glucose tolerance test—Subsequent to a 4-h fast, conscious mice were injected 
with D-glucose (1.5 mg/kg of body weight) intra-peritoneally. Blood was collected from the 
tail vein prior to glucose injection (time 0) and at 15, 30, 60, and 120 min post-injection. 
Blood glucose was deter- mined using a glucometer (Breeze contour, Bayer).
2.3.3. Insulin tolerance test—Mice were injected with insulin (0.75 U/kg of body 
weight) intra peritoneally after a 4-h fast. Blood glucose was measured using a glucometer at 
time 0, 15, 30, 60 and 90 min.
2.3.4. DNA extraction from pBabe retrovirus—DNA was extracted from pBabe-puro 
or -E4orf1 retrovirus stock using the viral DNA extraction kit (QIAamp MinElute Virus Spin 
kit, #57704, QIAGEN) following manufacturer’s instructions.
2.3.5. Titration for pBabe retrovirus—The E4orf1 plasmid (100 ng/μL or 1010 copies/
μL) was diluted 10 times to 101 copies/μL. The extracted retroviral DNA from the pBabe-
puro and pBabe-E4orf1 retrovirus stock was also diluted 10 times in DNase-free water. The 
samples or standard DNA (4 μL) was mixed with 2x TaqMan universal PCR Master Mix 
(#4304437, Applied Biosystems), primer and probe (PrimeTime Std qPCR Assay, 
#88953932, IDT) for E4orf1. The cDNA expression for E4orf1 was identified by quantative 
real-time PCR (ABI prism 7900HT). The titration of virus stock was calculated based on 
standard curve of E4orf1 plasmid.
2.3.6. ELISA for serum insulin—Serum from trunk blood was separated by 
centrifugation at 5000 rpm for 20 min and collected. Serum insulin was determined using a 
microtiter plate assay (Rat/Mouse Insulin ELISA, #EZRMI-13K, Millipore) as per 
manufacturer’s instructions and the plates were read at 450 nm and 590 nm absorbance on a 
plate reader.
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2.3.7. Western blot analyses—Proteins from adipose tissue, liver and skeletal muscle 
were used for western blot analyses by standard procedure previously described [4].
2.3.8. Glucose stimulated insulin secretion—832/13 cells are grown and passaged as 
described elsewhere [28]. For measurements of insulin secretion, cells were seeded into 12-
well dishes, grown to 90% confluence and then treated with virus overnight in standard 
culture media. Insulin secretion assays were performed as described [28]. Insulin was 
measured using the High Range Rat Insulin ELISA assay kit (Mercodia). After collection of 
media for insulin analysis, the cells were lysed in M-PER lysis reagent (Thermo Scientifc) 
and BCA assays (Thermo Scientific) performed. Insulin secretion was normalized to total 
protein content.
2.3.9. Beta cell mass determination—Pancreas samples were processed and 4–5 μm 
sections were cut every 150 μm through the entire pancreas block. At each step-point, three 
serial sections were collected then 150 μm were removed and another three serial sections 
collected. Typically this resulted in 7–10 sections being sufficient to cover the entire 
pancreas thickness. The sections were stained on the Leica BOND system using rabbit anti-
insulin antibody (Cell Signaling) at a 1:1000 dilution. The slides were dewaxed on the 
BOND and then subjected to a heat induced antigen retrieval using a low pH solution for 20 
min followed by primary antibody incubation for 30 min and subsequent polymer-based 
detection (DAB). Slides were dehydrated, cover-slipped, and scanned on the Hamamatsu 
NanoZoomer for down-stream analysis in the NDPView software and ImageJ.
2.3.10. Insulin vs glucagon intensity—Slides were dewaxed prior to heat induced 
antigen retrieval with Biocare Rodent Decloaker at 100 °C for 15 min. After cooling for 30 
min the slides were blocked for 1 h with goat serum block. Slides were incubated overnight 
at 4 °C with 1:400 dilutions of both Invitrogen guinea pig anti-insulin and Cell Signaling’s 
rabbit anti-glucagon antibodies. After 17 h, the slides were washed in TBST prior to 
incubation with 1:300 dilutions of Invitrogen’s goat anti-guinea pig Alexa 488 and 
Invitrogen’s goat anti-rabbit Alexa 594 secondary antibodies for 1 h at RT. The slides were 
then washed in TBST prior to counterstaining with Hoechst.
After mounting and allowing the slides to cure for about 1–2 h, the slides were imaged on a 
Leica DM6000 microscope. Images were collected using a Hamamatsu EM-CCD (512 × 
512 pixel) camera and were exported as single channel TIFF images for analysis in 
CellProfiler software. A CellProfiler pipeline was developed to identify insulin-positive beta 
cells as well as glucagon-positive alpha-cells based on green or red staining intensity, 
respectively. The area and integrated intensity of each cell type was collected and used to 
determine the average intensity of green (insulin) or red (glucagon) signal as well as the 
ratio of glucagon expressing vs insulin expressing cell area.
3. Results
3.1. E4orf1 enhances blood glucose excursion in high fat fed mice
pBabe vector expressed E4orf1 in mice tissue (Supplementary Fig. 1). Following an 
intraperitoneal glucose load, blood glucose excursion as determined by glucose tolerance 
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test (GTT) deteriorated when chow-fed 7-week old mice (n = 18) were switched to 60% (en
%) high fat diet for two weeks (Fig. 1A). At this time, they were divided in two weight -
matched groups (n = 9 each) and injected with either null virus vector (Control) or with 
virus vector expressing Ad36 E4orf1 (E4orf1). One week later, the E4orf1 group, but not the 
control group, significantly improved blood glucose clearance, as indicated by GTT and area 
under the curve (AUC) of GTT (Fig. 1B–E).
3.2. E4orf1 transiently but reproducibly enhances glucose excursion
Expression of E4orf1 in 9 week old mice on 60% fat diet, enhanced glucose excursion one 
week later, compared to that in control group of mice (Fig. 2A) and the effect persisted for 
one more week (Fig. 2B). The change in GTT due to E4orf1 expression was transient, as 
evident from GTT 3 and 4 week later which showed a lack of difference in GTT between the 
two groups (Fig. 2C & D). To test reproducibility of the effect, respective groups of mice 
were reinoculated with the null vector or E4orf1 expressing vector on week 7 after the first 
inoculation. As expected, the E4orf1 group improved GTT post re-inoculation (Fig. 2E & 
F).
3.3. A booster dose of E4orf1 does not extend the duration of enhancement in glucose 
clearance
Expression of E4orf1 in 9 week old mice on 60% fat diet, enhanced glucose clearance one 
week later, compared to that in control group of mice (Fig. 3A and B). A booster dose of 
respective vectors at this time did not extend the duration of enhancement in GTT by 
E4orf1, which continued till 2 week after the initial dose (Fig. 3C&D), but faded at 3 week 
post initial dose (Fig. 3E & F). A second booster given after the differences in GTT 
disappeared (Fig. 3E & F), again improved GTT for the E4orf group (Fig. 3G & H).
3.4. Longer duration of high fat diet delays the improvement in GTT induced by E4orf1
In mice on high fat diet for prior 8 weeks, E4orf1 expression did not improve GTT one week 
later (Fig. 4A & B). However, after a second dose of vectors after 3 weeks of the initial 
inoculation, E4orf1 significantly improved GTT (Fig. 4C & D). The improvement in GTT 
increased with the dose of E4orf1 vector (Fig. 4C & D).
3.5. E4orf1 improves glucose clearance without increasing insulin sensitivity, production 
or secretion
In high fat fed mice, E4orf1 enhanced glucose clearance 1 and 2 week later (Fig. 2 A & B), 
without an improvement in insulin sensitivity as determined by insulin tolerance test (ITT) 
(Fig. 5A–D). E4orf1 significantly reduced non-fasting insulin, but not the fasting insulin 
(Fig. 5E). E4orf1 does not appear to directly influence insulin production or secretion. 
Immuno-histology of mouse pancreatic islets showed no significant differences in alpha or 
beta cell areas or insulin or glucagon content in E4orf1 or Control groups (Tables 1 and 2). 
Rat insulinoma cells (832/13) infected with control or E4orf1 expressing pBabe retrovirus 
did not differ significantly from uninfected cells during assays measuring glucose stimulated 
insulin secretion (Fig. 5F).
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3.6. E4orf1 enhances cell signaling in glucose disposal pathway
In vitro studies show that Ad36 E4orf1 up-regulates the Ras/PI3K/AKT/Glut4 pathway and 
adiponectin abundance, which likely promotes cellular glucose uptake [25,26]. The 
abundance of selected proteins in glucose disposal pathway was compared between the 
Control and E4orf1 groups in skeletal muscle, adipose tissue and liver. Compared to the 
Control group, E4orf1 significantly increased the abundance of p-AKT and glucose 
transporter Glut4 in skeletal muscle at the site of injection (right thigh) (Fig. 6 A & B). 
E4orf1 significantly increased the abundance of adiponectin protein in inguinal and 
retroperitoneal fat pads (Fig. 6C & D), and that of Ras in inguinal fat pad (Fig. 6C & D). No 
significant differences were detected in the protein abundance of Glut4, PPARγ, or p-AKT 
in fat pads of the two groups (Fig. 6C & D). Of the liver proteins compared, E4orf1 
significantly influenced the abundance of only Glucose transporter 2 (Glut 2), but not p-
AKT or p-AMPK or glucokinase (Fig. 6E).
4. Discussion
We first observed the anti-hyperglycemic effect of adenovirus 36 in rats and chow or high fat 
fed mice [4,5]. Subsequent in vitro experiments narrowed down the effect to E4orf1 protein 
of adenovirus 36. Therefore, to test the anti-hyperglycemic effect of E4orf1 in vivo, we used 
high fat fed mice, a model that resembles human diet-induced hyperglycemia. This mouse 
model improved glycemic control transiently but predictably and reproducibly, in response 
to E4orf1 booster doses. Recently, Kusminski et al. [29] also inducibly expressed E4orf1 in 
adipose tissue of high fat fed mice to improve glycemic control, indicating suitability of the 
model to further study the phenomenon.
Multiple separate experiments reproducibly demonstrated the potential of Ad36 E4orf1 
protein to enhance blood glucose clearance in mice in presence of high fat diet. We 
determined E4orf1 protein expression in muscle and liver via PCR (Supplemental 
information). Considering that Ad36E4orf1 is a viral protein and administered exogenously, 
its expression is too low in tissues for detection by western blotting. Therefore we instead 
determined the presence of E4orf1 DNA in tissue by PCR as evidence of Ad36E4orf1 
presence.
Collectively, these experiments indicate that the capability of Ad36 to improve glycemic 
control [4,5] can be successfully captured by expressing its E4orf1 protein in vivo. Although 
previous studies revealed that Ad36 E4orf1 is necessary and sufficient to enhance cellular 
glucose uptake in vitro [26], improvement by E4orf1 in glucose excursion in vivo after a 
glucose challenge is a pivotal finding. This provides the proof of concept for further 
development of E4orf1 as an anti-diabetic agent. Nonetheless, as discussed below, several 
aspects need to be considered before E4orf1 could be translated to a therapeutic use.
Much of the understanding of in vitro molecular interaction of E4orf1was initially based on 
the information about E4orf1 protein of human adenovirus 9 (Ad9), which bears a 92% 
sequence homology with E4orf1 of Ad36. E4orf1 proteins have a PDZ domain binding 
motif (PBM) at the C-terminal. Through its PBM, the peptide binds to PDZ proteins, which 
are scaffolding proteins that facilitate protein interactions. E4orf1 proteins of Ad9 as well as 
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Ad36 require their PBM for binding to Dlg (Drosophila disc large)-1 protein. After the 
binding in cytosol, the complex travels to the cell membrane, where it activates Ras and 
subsequently, PI3K [30–32]. Ad36 E4orf1requires intact PBM for Ras induction, and 
downstream activation of AKT signaling and glucose uptake [26].
As the first investigation of its kind, this study mapped out a number of fundamental 
attributes of the in vivo action of Ad36 E4orf1. A key feature is that the improvement in 
glycemic control is transient, yet reproducible, upon re-introduction of E4orf1. This 
indicates that probably, the effect is transient due to diminishing E4orf1 expression over 2 
weeks, and not due to development of resistance to the action of E4orf1 itself. Although the 
retrovirus vector pBabe-puro used for E4orf1 expression should stably integrate in host 
DNA and provide a longer lasting expression of E4orf1, the gene expression and hence the 
effect of E4orf1 appears to last only a few days in vivo. In fact, the transient effect of E4orf1 
on glucose clearance helps demonstrate the reproducibility of response of mice when 
exposed to E4orf1. Although this study was not designed to systematically evaluate E4orf1 
dose response, a further decrease in AUC of GTT in response to a booster dose (Fig. 3D) or 
greater amount of vector (300 vs 600 μL) (Fig. 4B) suggested that the reduction in glucose 
excursion is related to E4orf1 dose.
Another important attribute is that E4orf1 appears to promote blood glucose clearance 
independent of insulin involvement. Although, enhanced sensitivity, production or release of 
insulin, or a decrease in insulin antagonism by glucagon are some key determinants of 
glucose excursion after a glucose load [33], E4orf1 did not modulate them (Fig. 5, Tables 1 
and 2). Instead, it is proposed that the insulin requirement for controlling glucose disposal is 
reduced in presence of E4orf1, termed as the insulin sparing effect of E4orf1 [34]. This was 
also apparent from a reduction in non- fasting serum insulin levels in E4orf1 (Fig. 5E). 
Fasting serum insulin was not different between the E4orf1 expressing or control mice. 
However serum insulin was significantly lower in E4orf1 expressing animals under fed 
conditions. The combination of better glucose clearance and lower insulin levels suggests 
that these mice cleared post-prandial glucose increase without increasing insulin secretion. 
This could be considered as insulin sparing action of E4orf1. Improved glucose clearance as 
seen in this study is consistent with a decrease in circulating insulin because insulin 
resistance and insulin secretion are positively correlated. Thus, E4orf1 delivery appears to 
enhance glucose clearance in a manner analogous to exercise, i.e., by stimulating uptake into 
tissues such as skeletal muscle without requiring insulin.
Ad36 and E4orf1 protein bypass the proximal insulin signaling, and increase cellular 
glucose uptake independent of insulin stimulation, by Ras-mediated up-regulation of AKT 
and Glut4 signaling in cells of adipose tissue and skeletal muscle [26,34]. Moreover, Ad36 
and E4orf1 reduce hepatic Glut2 protein abundance [4], which may contribute to the 
reduction in glucose output by hepatocytes [25]. Taken together, it is postulated that E4orf1 
improves glycemic control by increasing skeletal muscle and adipose tissue glucose uptake, 
and by reducing hepatic glucose output, independent of insulin action. In accordance, we 
observed greater abundance of Ras, p-AKT, Glut4 and adiponectin, and a reduction in 
hepatic Glut2 (Fig. 6) in some, but not in all tissues examined. pBabe vectors were 
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introduced by intraperitoneal, intra-muscular and subcutaneous routes in select sites. This 
may have led to non-uniform tissue distribution of E4orf1 expression.
Additional in vivo studies are needed to further elucidate how E4orf1 modulates cellular 
insulin signaling and to identify specific tissue contribution to systemic glucose levels. 
Nonetheless, considering that diabetes is often linked with insulin resistance or impaired 
proximal insulin signaling [35], the insulin sparing property of E4orf1 is attractive. It is also 
interesting that E4orf1 improved glycemic control despite a very high fat intake. This is 
particularly important because excessive kcal intake from lipid sources is often linked with 
weight gain, insulin resistance and diabetes [36]. Although a reduction in dietary fat intake 
and weight loss are often recommended as adjunct to diabetes treatment, making such 
dietary changes is highly challenging for many individuals [37]. Hence, the ability of E4orf1 
to improve glycemic control in presence of high fat diet is particularly valuable by providing 
options other than weight loss to control glycemia.
While this study provided critical impetus to harnessing the potential of Ad36 E4orf1 as a 
novel anti-diabetic agent in a model of diet-induced hyperglycemia, considerable research is 
needed to effectively exploit its therapeutic property. This includes a determination of the 
role of E4orf1 in preventing and treating diabetic in genetic models of obesity and diabetes, 
and in models of type 1 diabetes. Furthermore, a very careful evaluation of safety of long 
term exposure to E4orf1 is needed. Given the potential role of Ras in tumorogenesis [38], 
the in vivo effect of E4orf1 requires careful investigation. However, Ras activation is 
important for regular cell functioning and the role of Ras in tumorogenesis is mainly 
attributed to missense mutation leading to uncontrolled Ras expression [38]. Whereas, Ras 
overexpression was shown to improve glycemic control without any tumor formation [39]. 
No tumors were observed in previous experiments when animals were infected with Ad36. 
Nonetheless, the consequence of Ras modulation by E4orf1 [31] should be further evaluated. 
Finally, an effective approach is needed to therapeutically deliver E4orf1 or E4orf1 mimetic 
agents.
Conceptually, these findings open a research opportunity to develop a new anti-diabetic 
agent with multiple uniquely beneficial properties. This may lead to the translation of a 
rather unconventional source, microbial proteins, for therapeutic benefit.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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E4orf1 enhances blood glucose excursion in high fat fed mice: A. Eighteen, weight-matched 
7 week old C57Bl/6J male mice on chow diet were divided into two groups (Control; n = 9 
and E4orf1; n = 9) followed by baseline glucose tolerance test (GTT; black solid line). The 
mice were fed a 60% kcal high fat (HF) diet for 2 week and GTT performed (black dotted 
line). The animals were inoculated with pBabe retrovirus expressing control puro (B–C) or 
Ad36 E4orf1 (D–E) and GTT performed 1 week post inoculation. (*p < 0.05, **p < 0.005, 
***p < 0.0005). The bar graphs show area under the curve for respective groups.
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E4orf1 transiently but reproducibly enhances glucose excursion: C57BL/6J (9 week old) 
mice on 60% fat diet since 6 week of age were inoculated with pBabe-puro retrovirus 
(control; black solid lines, n = 6), or with pBabe expressing E4orf1 (black dotted lines; n = 
6). Expression of E4orf1, enhanced blood glucose clearance 1 week later, compared to 
control group of mice (A) and the effect persisted for one more week (B). The effect of 
E4orf1 on GTT was transient and weeks 3 and 4 post-inoculation (p.i.) showed that the 
effect of first inoculation had faded (C–D). Upon re-inoculation in week7, GTT significantly 
improved again for the E4orf1 group 4 d (E) and a week later (F). (*p < 0.05, **p < 0.005).
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A booster dose of E4orf1 does not extend the duration of enhancement in glucose clearance: 
Nine week old C57BL/6J (9 wk old) male mice on 60% HF diet since 6 wk of age were 
inoculated with control retrovirus (black solid lines, n = 6), or with E4orf1 (black dotted 
lines; n = 6). GTT was performed 1 week p.i. (A–B) and mice were re-inoculated at 10 week 
of age and GTT performed 1 week post re-inoculation (C–D). The improved glucose 
clearance following each inoculation disappeared 3 week post initial inoculation (E–F) but a 
second booster inoculation again improved GTT for the E4orf1 group (G–H). (*p < 0.05, 
**p < 0.005). The bar graphs show area under the curve for respective groups.
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Longer duration of high fat diet delays the improvement in GTT induced by E4orf1: 
Fourteen week old C57BL/6J male mice on 60% fat diet (since 6wk) were inoculated with 
pBabe-puro (control; black solid lines/bars, n = 6), or with different doses of pBabe 
expressing E4orf1 (300 μL dose; black dotted lines/bar, n = 6 and 600 μL dose; black big 
dotted lines/bar, n = 6). E4orf1 expression does not improve blood glucose clearance 1 week 
p.i. (A–B). A booster dose of the respective vectors 3 week post initial inoculation 
significantly improved effect of E4orf1 on GTT (C–D). (*p < 0.05, **p < 0.005, ***p < 
0.0005). The bar graphs show area under the curve for respective groups.
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E4orf1 improves glucose clearance without increasing insulin sensitivity, production or 
secretion: Insulin tolerance test (ITT) was performed 1 and 2 week post initial inoculation of 
control retrovirus (black solid lines, n = 3), or with E4orf1 (black dotted lines; n = 3) in 9 wk 
old HF fed C57Bl/6j male mice (A–D). The bar graphs (B & D) show area under the curve 
for respective groups. Serum insulin determined from fasted and non-fasted control (n = 3) 
and E4orf1 (n ¼ 3) inoculated mice (E). Groups were compared using ANOVA followed by 
tukey’s test (*p < 0.05). (F): 832/13 cells were transduced with the indicated viruses 
overnight. The 832/13 cells were incubated at the designated glucose concentrations for 2 h. 
Insulin secreted into the medium was measured by ELISA, normalized to total cellular 
protein, and was expressed as a fold increase relative to insulin secreted at 2 mmol/l glucose 
in cells that received no virus. Data represent the means ± SE for three independent 
experiments.
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E4orf1 enhances cell signaling in glucose disposal pathway: The glucose disposal pathway 
signaling in muscle, adipose tissue depots, and liver of control (n = 3) and E4orf (n = 3) 
mice was determined by western blotting. Muscle (A–B): p-Akt, p-AMPK, and Glut4 
expressions were normalized to t-Akt, t-AMPK, and GAPDH, respectively. Adipose tissue 
(C–D): Glut4, adiponectin, RAS, PPARγ, expressions were normalized to GAPDH, p-Akt 
was normalized to t-Akt. Liver (E–F): Glut2, glucokinase expressions were normalized to 
GAPDH, p-Akt, p-AMPK were normalized to t-Akt or t-AMPK, respectively. Groups were 
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compared using ANOVA followed by Tukey’s test. Only comparisons that were statistically 
significant (*p < 0.05, **p < 0.01) are presented as bar graphs.
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Table 1
Pancreatic beta cell mass.
Tissue area mm2 Islet area μm2 Islet fraction % Avg islet size μm2
Control (mean) 162.52   1,240,864 0.76 6151.31
Control (SD) 15.60 172,236 0.13   951.42
E4orf1 (mean) 190.39   1,413,198 0.73 5767.87
E4orf1 (SD) 28.30 538,512 0.26 1462.90
TTEST (p value) 0.20        0.62 0.86    0.72





































































































































































































































   
   
0.
28









   







Biochimie. Author manuscript; available in PMC 2016 November 28.
